MAPT and Alzheimer disease: Immunotherapy addressing tau pathology has been less extensively investigated, but may represent a better target, since this pathology correlates better with AD cognitive symptoms (Nelson et al., 2012; Götz and Götz, 2019; Plotkin and Cashman, 2020; Soeda and Takashima, 2020).